tHEORetically Speaking
Getting Real About Real-World Data
The terms “Real-World Data” (RWD) and “Real-World Evidence” (RWE) are often thrown around in the life science industry, but what do they really mean? For our latest vlog, we spoke with Bill Saunders, PhD, MPH, from Integra Connect to learn about RWD and RWE in the context of [...]
Podcast Q&A: Advancing Patient Care through Real-World Data, Machine Learning, and Systems Biology
This podcast segment from Syapse's September 21, 2022 webinar features the Q&A with Nitin Baliga, Insitute of Systems Biology, and Thomas Brown, Syapse as they answer questions on utilizing real-world data, machine learning, and systems biology for benefiting therapeutic development. If you do not see the embedded media [...]
Podcast Q&A: Accelerating the Generation of Payer Insights and Evidence Across the Product Lifecycle to Achieve Optimal Access
This tHEORetically Speaking podcast episode highlights the Q&A from Genesis Research's October 20, 2022 webinar and features Priti Jhingran and Tijana Ignjatovic as they answer questions on opportunities for using agile platforms and fit-for-purpose engagement models that can drive an iterative approach to obtaining payer insights and developing impactful evidence [...]
Podcast: How Accelerated Drug Development Requires Disruption in Market Access and Pricing
We recently sat down with Preeti Patel, MPharm, CEO and Founder of Global Pricing Innovations (GPI), to learn what is driving the growing importance for early stage asset value and price prediction, how GPI is supporting clients through these challenges, and how this solution was developed. GPI is a price [...]
How might digitization change health care in Germany by 2035, Julian Molitor?
Digital health could improve the efficiency, care and way patients are treated in all health care systems in the next years. Germany has started by implementing digital health applications (“DIGAs”) and is currently on its way to improve the digital infrastructure in hospitals. Some core questions remain, such as reimbursement [...]
Are selective contracts with German insurances a smarter reimbursement pathway, Tim Hering?
Within the opportunity of contracting in the German health care market, prices, reimbursement and integrated care paths could be agreed on. However, for some medical devices, especially in the outpatient setting, selective contracts could be the most attractive pathway to enter into reimbursement agreements. But which health insurance companies should [...]
Would AI substitute or (only) support market access managers, Dr. Andree Bates?
Dr Stefan Walzer, market access expert, and his guest Dr. Andree Bates, expert in artificial intelligence (AI), are discussing the future of market access within the health care industry. How could AI support market access planning, submissions and negotiations, especially with the ever-increasing data? How could AI be beneficial in defining an [...]
Using Real-World Data for Patients with Multiple Sclerosis: A New Machine Learning Model for the Expanded Disability Status Scale (EDSS)
Multiple sclerosis (MS) is a chronic illness in which the body’s immune system attacks myelin, the substance that surrounds and protects the nerve fibers of the central nervous system. The result is a disabling disease that causes damage to the brain and spinal cord over time. Symptoms vary from [...]
Podcast Q&A: Evidence Generation Planning
This podcast segment from Syneos Health's July 26, 2022 webinar features the Q&A with Colin Oliver, Anila Dede, Erwin De Cock, and Arshi Gupta as they answer questions on evidence generation planning for clinical and commercial success and improvement of patient outcomes. If you do not see the [...]
How successful is the DiGA fast track, Dr. Henrik Matthies?
Dr. Matthies used to be at the epicenter of the DIGA launch in 2020. He was the managing director of the Health innovation hub: digital health think tank of the federal ministry of health in Germany. The first project of agile lawmaking in Germany. What are key takeaways and learnings from 2 [...]
The UK market access has always been complex, now even more than before, Graham Foxon and Paul Craddy?
The UK has always been on the forefront of market access with its unique pathways within England, but especially also considering Wales, Ireland and Scotland as well. Furthermore, since the Brexit there were new innovation paths introduced. The core question remains, how one could identify the optimal path for their product (including [...]
How to Change Clinical Practice Using Health Economics and Outcomes Research
In 2005 and 2009, I published HEOR studies that led to an 80% drop in the number of US women who had their ovaries removed at the time of hysterectomy. Over the 17 years since our first paper came out, the practice has almost disappeared. A recent study reported [...]
Switzerland is strong in many aspects, so also in its health care system, Dr. Peter Indra?
The Swiss healthcare system is rather complex but at the same time quite effective. High expenditures into health care corresponds with high life expectancy. However, what are the core processes in Switzerland with regards to health care delivery? What is the path towards innovation pricing and new price models? And what [...]
Syneos Health Medical Affairs Spotlight
Supplier Spotlight® highlights the unique skills and services offered by organizations who are part of our CONNECTED COMMUNITY™. We recently spoke with experts from Syneos Health Medical Affairs about how their organization is uniquely positioned to address the changing dynamics in the healthcare landscape with the increased emphasis on engagement [...]
AMNOG was the end of paradise for pharmaceutical companies, correct Prof. Hammerschmidt?
What have been the main changes after 10 years of AMNOG for pharmaceutical companies? What have been the biggest successes within these years? For orphan drug the benefit evaluation process was eased in order to keep incentives high. Have price expectations been up met - by both sides? After 10 [...]